Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jul;30(1):97–106. doi: 10.1111/j.1365-2125.1990.tb03748.x

Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.

S Karhuvaara 1, A Kallio 1, M Scheinin 1, M Anttila 1, J S Salonen 1, H Scheinin 1
PMCID: PMC1368280  PMID: 1975199

Abstract

1. Single doses (10, 30 and 100 mg) of atipamezole (MPV-1248), a new potent and selective imidazole-type alpha 2-adrenoceptor antagonist, and saline placebo were administered as 20 min intravenous infusions to six healthy male volunteers in a randomized double-blind, cross-over phase I study. Later, 100 mg atipamezole was given orally to the same subjects in an open fashion. 2. The i.v. doses resulted in linearly dose-related concentrations of atipamezole in plasma. Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1. No atipamezole could be detected in plasma after oral dosing. 3. Subjective drug effects were seen mainly after the largest i.v. dose and included increased alertness and nervousness, coldness and sweating of hands and feet, tremor and shivering, motor restlessness, and increased salivation. Salivation was also quantitated using dental cotton rolls, with dose-related increases produced by the i.v. doses. 4. The 100 mg i.v. dose increased plasma noradrenaline concentrations on average by 484 +/- 269 (s.d.)%, and also elevated both systolic and diastolic blood pressure (mean increases 17 +/- 7/14 +/- 2 mm Hg). The 30 mg dose had minor and the 10 mg dose no effects on these variables. Adrenaline and cyclic AMP levels in plasma were increased only after the largest dose. No drug effects were observed after oral dosing. 4. Plasma C-peptide and blood glucose levels were not markedly influenced by the drug, and cortisol secretion was not stimulated. 5. The observed effects are compatible with the presumed alpha 2-adrenoceptor antagonistic action of atipamezole and are in general concordance with the reported results of other alpha 2-adrenoceptor antagonists (yohimbine and idazoxan). 6. Although not orally active, atipamezole may prove to be a useful agent in studies of alpha 2-adrenoceptor function in man.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bremmelgaard A. Analysis of vanillylmandelic and homovanillic acids in urine using solid phase sample preparation and high pressure liquid chromatography with electrochemical detection. Scand J Clin Lab Invest. 1985 Sep;45(5):387–391. doi: 10.3109/00365518509155233. [DOI] [PubMed] [Google Scholar]
  2. Brown M. J., Struthers A. D., Burrin J. M., Di Silvio L., Brown D. C. The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man. Br J Clin Pharmacol. 1985 Dec;20(6):649–658. doi: 10.1111/j.1365-2125.1985.tb05124.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown M. J., Struthers A. D., Di Silvio L., Yeo T., Ghatei M., Burrin J. M. Metabolic and haemodynamic effects of alpha 2-adrenoceptor stimulation and antagonism in man. Clin Sci (Lond) 1985;68 (Suppl 10):137s–139s. doi: 10.1042/cs068s137. [DOI] [PubMed] [Google Scholar]
  4. Brown M. J., Struthers A. D., di Silvio L. Peripheral alpha 2 adrenoceptor stimulation contributes to the sympatholytic effect of guanfacine in humans. J Cardiovasc Pharmacol. 1985;7 (Suppl 6):S159–S161. doi: 10.1097/00005344-198500076-00027. [DOI] [PubMed] [Google Scholar]
  5. Bylund D. B., Ray-Prenger C., Murphy T. J. Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther. 1988 May;245(2):600–607. [PubMed] [Google Scholar]
  6. Doxey J. C., Roach A. G., Smith C. F. Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors. Br J Pharmacol. 1983 Mar;78(3):489–505. doi: 10.1111/j.1476-5381.1983.tb08809.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Elliott H. L., Jones C. R., Vincent J., Lawrie C. B., Reid J. L. The alpha adrenoceptor antagonist properties of idazoxan in normal subjects. Clin Pharmacol Ther. 1984 Aug;36(2):190–196. doi: 10.1038/clpt.1984.161. [DOI] [PubMed] [Google Scholar]
  8. Fairfax A. J., Rehahn M., Jones D., O'Malley B. Comparison between the effects of inhaled isoprenaline and fenoterol on plasma cyclic AMP and heart rate in normal subjects. Br J Clin Pharmacol. 1984 Feb;17(2):165–170. doi: 10.1111/j.1365-2125.1984.tb02332.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Foucart S., Nadeau R., de Champlain J. The release of catecholamines from the adrenal medulla and its modulation by alpha 2-adrenoceptors in the anaesthetized dog. Can J Physiol Pharmacol. 1987 Apr;65(4):550–557. doi: 10.1139/y87-093. [DOI] [PubMed] [Google Scholar]
  10. Goldberg M. R., Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983 Sep;35(3):143–180. [PubMed] [Google Scholar]
  11. Green G. J., Wilson H., Yates M. S. The effect of clonidine on centrally and peripherally evoked submaxillary salivation. Eur J Pharmacol. 1979 Jan 15;53(3):297–300. doi: 10.1016/0014-2999(79)90136-5. [DOI] [PubMed] [Google Scholar]
  12. Hamilton W. K. Fashion, Darwin, and anesthetics as poisons. Anesthesiology. 1988 Dec;69(6):811–812. doi: 10.1097/00000542-198812000-00001. [DOI] [PubMed] [Google Scholar]
  13. Hjemdahl P., Freyschuss U., Juhlin-Dannfelt A., Linde B. Differentiated sympathetic activation during mental stress evoked by the Stroop test. Acta Physiol Scand Suppl. 1984;527:25–29. [PubMed] [Google Scholar]
  14. Jouve J., Mariotte N., Sureau C., Muh J. P. High-performance liquid chromatography with electrochemical detection for the simultaneous determination of the methoxylated amines, normetanephrine, metanephrine and 3-methoxytyramine, in urine. J Chromatogr. 1983 May 13;274:53–62. doi: 10.1016/s0378-4347(00)84408-4. [DOI] [PubMed] [Google Scholar]
  15. Kallio A., Scheinin M., Koulu M., Ponkilainen R., Ruskoaho H., Viinamäki O., Scheinin H. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther. 1989 Jul;46(1):33–42. doi: 10.1038/clpt.1989.103. [DOI] [PubMed] [Google Scholar]
  16. Kashiwagi A., Harano Y., Suzuki M., Kojima H., Harada M., Nishio Y., Shigeta Y. New alpha 2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients. Diabetes. 1986 Oct;35(10):1085–1089. doi: 10.2337/diab.35.10.1085. [DOI] [PubMed] [Google Scholar]
  17. Keselman H. J., Keselman J. C. The analysis of repeated measures designs in medical research. Stat Med. 1984 Apr-Jun;3(2):185–195. doi: 10.1002/sim.4780030211. [DOI] [PubMed] [Google Scholar]
  18. Langer S. Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1980 Dec;32(4):337–362. [PubMed] [Google Scholar]
  19. Limone P., Cagliero E., Massara F., Molinatti G. M. Reduced glucose tolerance after guanfacine in normal and obese subjects. Horm Metab Res. 1983 Jul;15(7):352–352. doi: 10.1055/s-2007-1018717. [DOI] [PubMed] [Google Scholar]
  20. Longnecker D. E. Alpine anesthesia: can pretreatment with clonidine decrease the peaks and valleys? Anesthesiology. 1987 Jul;67(1):1–2. [PubMed] [Google Scholar]
  21. Mattila M., Seppala T., Mattila M. J. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. 1988 Jul;3(3):215–229. doi: 10.1097/00004850-198807000-00003. [DOI] [PubMed] [Google Scholar]
  22. Metz S. A., Halter J. B., Robertson R. P. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha-adrenergic pathways. Diabetes. 1978 May;27(5):554–562. doi: 10.2337/diab.27.5.554. [DOI] [PubMed] [Google Scholar]
  23. Murphy M. B., Brown M. J., Dollery C. T. Evidence for a peripheral component in the sympatholytic actions of clonidine and guanfacine in man. Eur J Clin Pharmacol. 1984;27(1):23–27. [PubMed] [Google Scholar]
  24. Nakaki T., Nakadate T., Kato R. Alpha 2-adrenoceptors modulating insulin release from isolated pancreatic islets. Naunyn Schmiedebergs Arch Pharmacol. 1980 Aug;313(2):151–153. doi: 10.1007/BF00498572. [DOI] [PubMed] [Google Scholar]
  25. Ostenson C. G., Pigon J., Doxey J. C., Efendic S. Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. J Clin Endocrinol Metab. 1988 Nov;67(5):1054–1059. doi: 10.1210/jcem-67-5-1054. [DOI] [PubMed] [Google Scholar]
  26. Price L. H., Charney D. S., Rubin A. L., Heninger G. R. Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine. Arch Gen Psychiatry. 1986 Sep;43(9):849–858. doi: 10.1001/archpsyc.1986.01800090035006. [DOI] [PubMed] [Google Scholar]
  27. Ramage A. G., Tomlinson A. The effect of yohimbine, WY 26392 and idazoxan on sympathetic nerve activity. Eur J Pharmacol. 1985 Feb 26;109(2):153–160. doi: 10.1016/0014-2999(85)90416-9. [DOI] [PubMed] [Google Scholar]
  28. Reid J. L. The Fourth Lilly Prize Lecture, University of Aberdeen, September 1980. The clinical pharmacology of clonidine and related central antihypertensive agents. Br J Clin Pharmacol. 1981 Sep;12(3):295–302. doi: 10.1111/j.1365-2125.1981.tb01217.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sakurai S., Wada A., Izumi F., Kobayashi H., Yanagihara N. Inhibition by alpha 2-adrenoceptor agonists of the secretion of catecholamines from isolated adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(1):15–19. doi: 10.1007/BF00647832. [DOI] [PubMed] [Google Scholar]
  30. Scheinin M., Kallio A., Koulu M., Viikari J., Scheinin H. Sedative and cardiovascular effects of medetomidine, a novel selective alpha 2-adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol. 1987 Oct;24(4):443–451. doi: 10.1111/j.1365-2125.1987.tb03196.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Scheinin M., Koulu M., Laurikainen E., Allonen H. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol. 1987 Nov;24(5):645–653. doi: 10.1111/j.1365-2125.1987.tb03224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Struthers A. D., Brown D. C., Brown M. J., Schumer B., Bloom S. R. Selective alpha 2 receptor blockade facilitates the insulin response to adrenaline but not to glucose in man. Clin Endocrinol (Oxf) 1985 Nov;23(5):539–546. doi: 10.1111/j.1365-2265.1985.tb01114.x. [DOI] [PubMed] [Google Scholar]
  33. Virtanen R., Savola J. M., Saano V. Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. Arch Int Pharmacodyn Ther. 1989 Jan-Feb;297:190–204. [PubMed] [Google Scholar]
  34. Warren J. B., Dollery C. T., Fuller R. W., Williams V. C., Gertz B. J. Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103–109. doi: 10.1038/clpt.1989.113. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES